CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, today announced that safety and efficacy data from the Company’s Phase 1 and Phase 2 V-HEALTH (Vascular intimal Hyperplasia: Extending Arterial and venous patency, Limiting vascular Trauma, and inhibiting Hyperplasia while re-establishing vascular health) trials will be presented at the 35th Annual VEITHsymposium™ in New York City, New York. In V-HEALTH, Vascugel® is being studied in patients with end-stage renal disease that need permanent arteriovenous (AV) access for hemodialysis.
